Saturday, February 14, 2026 2/14/2026

USING VSV VECTORS TO DISPLAY AND EVOLVE NOVEL HIV ENVELOPE IMMUNOGENS

Award Number: R01AI084840
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/10/2009
PERIOD OF PERFORMANCE END DATE: 08/31/2014

Group Awards By:

View Award Description

USING VSV VECTORS TO DISPLAY AND EVOLVE NOVEL HIV ENVELOPE IMMUNOGENS - DESCRIPTION (provided by applicant): The objective of this Program is to design and develop three classes of highly novel HIV-1 vaccine immunogens based on the critical viral envelope (Env) protein, and subsequently test these vaccine candidates to determine their capacity to elicit broadly neutralizing antibody responses required to provide protection from HIV infection. Vesicular stomatitis virus (VSV) vectors take on strategic roles in design, development and delivery of these new vaccine candidates. The three new immunogen platforms are designed specifically for expression by VSV vectors as transmembrane proteins that will present epitopes to the immune system in several natural contexts including; on the surfaces of vector particles in the vaccine, in the membrane of infected cells following vaccination, and on the surface of progeny virus particles produced in the vaccinated host. The novel immunogen platforms that will be developed include: i) stable Env trimers optimized for expression by VSV; ii) Env epitopes derived from the membrane-proximal external region (MPER) displayed with a VSV G carrier molecule or scaffold; and iii) MPER epitopes presented in a membrane- proximal environment with a truncated G protein platform called G-Stem. Moreover, a novel process will be developed that makes use of the innate and dynamic ability of VSV to genetically adapt, through accrual of mutations, to biologically derived unique immunogen configurations, which will exhibit enhanced characteristics such as improved expression, greater abundance in viral and cellular membranes, increased stability, or critical epitope exposure and conformation. Experimental vaccines will be tested, characterized and ranked 'in vitro' before top candidates are advanced into rabbit immunogenicity studies to assess the character of the humoral immune response directed by the new vaccines. Candidate vaccines that elicit broadly neutralizing antibody responses in rabbits will be evaluated in a macaque challenge protection model. Antibody responses in vaccinated macaques will be evaluated thoroughly, and then animals will be challenged with a pathogenic hybrid simian/human immunodeficiency virus (SHIV) to assess vaccine efficacy. Project Relevance: Three new experimental vaccines will be developed specifically to stimulate the immune system to produce antibody responses against HIV-1. These vaccines will be developed using a novel methodology to biologically evolve candidates that elicit robust immune responses against specific regions of the HIV envelope protein. Promising vaccine candidates will be evaluated systematically in animal models to determine whether they elicit antibody responses that are more efficacious than those produced with earlier experimental vaccines.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2013 ( Subtotal = $477,940 )
2013	2013	INTERNATIONAL AIDS VACCINE INITIATIVE	110 WILLIAM STREET	NEW YORK	NY	10038	NEW YORK	USA	Allergy and Infectious Diseases Research	000	5	7/18/2013	NON-COMPETING CONTINUATION	$477,940
														Subtotal = $477,940

Issue Date FY: 2012 ( Subtotal = $451,019 )
2012	2012	INTERNATIONAL AIDS VACCINE INITIATIVE	110 WILLIAM STREET	NEW YORK	NY	10038	NEW YORK	USA	Allergy and Infectious Diseases Research	000	4	8/2/2012	NON-COMPETING CONTINUATION	$451,019
														Subtotal = $451,019

Issue Date FY: 2011 ( Subtotal = $365,775 )
2011	2011	INTERNATIONAL AIDS VACCINE INITIATIVE	110 WILLIAM STREET	NEW YORK	NY	10038	NEW YORK	USA	Allergy and Infectious Diseases Research	000	3	7/27/2011	NON-COMPETING CONTINUATION	$365,775
														Subtotal = $365,775

Issue Date FY: 2010 ( Subtotal = $380,523 )
2010	2010	INTERNATIONAL AIDS VACCINE INITIATIVE	110 WILLIAM STREET	NEW YORK	NY	10038	NEW YORK	USA	Allergy and Infectious Diseases Research	001	2	8/31/2010	NON-COMPETING CONTINUATION	$380,523
2010	2009	INTERNATIONAL AIDS VACCINE INITIATIVE	110 WILLIAM STREET	NEW YORK	NY	10038	NEW YORK	USA	Allergy and Infectious Diseases Research	000	1	11/27/2009	NEW	$0
														Subtotal = $380,523

Issue Date FY: 2009 ( Subtotal = $354,595 )
2009	2009	INTERNATIONAL AIDS VACCINE INITIATIVE	110 WILLIAM STREET	NEW YORK	NY	10038	NEW YORK	USA	Allergy and Infectious Diseases Research	000	1	9/4/2009	NEW	$354,595
														Subtotal = $354,595

Grand Total All Awards = $2,029,852

Top

All Categories

About

Search

Reports

Data Submission

Award Information

USING VSV VECTORS TO DISPLAY AND EVOLVE NOVEL HIV ENVELOPE IMMUNOGENS

Award Number: R01AI084840

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/10/2009

PERIOD OF PERFORMANCE END DATE: 08/31/2014

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer